Overview

Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The central aim of this trial is to investigate the safety and tolerability of Phage Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns susceptible to infection/or infected by S. aureus, P. aeruginosa, or K. pneumoniae species. It is hypothesized that no adverse events, clinical abnormalities, or changes in laboratory tests results related to the application of Phage Cocktail SPK Spray will be observed.
Phase:
Phase 1
Details
Lead Sponsor:
Phagelux Inc.
Treatments:
Gramicidin
Neomycin
Nystatin
Triamcinolone Acetonide